Day: January 17, 2021

WICHITA, Kan., Jan. 17, 2021 (GLOBE NEWSWIRE) — Equity Bancshares, Inc. (NASDAQ:EQBK), (“Equity”), the Wichita-based holding company of Equity Bank, will release its fourth quarter 2020 results on Monday, January 25, 2021, with a press release issued after market close.Equity Chairman and Chief Executive Officer Brad Elliott and Chief Financial Officer Eric Newell will hold a conference call and webcast to discuss fourth quarter 2020 results on Tuesday, January 26, 2021 at 10 a.m. eastern time or 9 a.m. central time.Investors, news media, and other participants should register for the call or webcast at investor.equitybank.com. Participants may dial into the call toll-free at (844) 534-7311 from anywhere in the U.S. or (574) 990-1419 internationally, using conference ID no. 6781789.Participants are encouraged to dial into the call...

PRFoods unaudited preliminary consolidated turnover in the 2nd quarter of the financial year 2020/2021 amounted to 17.07 million euros. Compared to the previous quarter i.e. the 1st quarter, the sales increased by 33.9%, (1Q 2020/2021: 12.74 million euros), with retail sector increased by 30.7%, wholesale by 43.6% and HoReCa sector by 14.2%. Compared to last year same period, sales decreased by 32.9% (2Q 2019/2020: 25.43 million euros), decrease in HoReCa by 52.7% and in wholesale by 60.9%. Sales increased in retail sector by 3.2%Indrek Kasela, CEO, PRFoods:„The impact of COVID-19 continues in fish sector and as we noted in last sales announcement, HoReCa sector which gives ca 1/3 of salmon- and troutbusiness both globally and regionally, will not recover to previous levels in next 12 months. End of the year brought Christmas lockdowns...

PRFoodsi 2020/2021. aasta teise kvartali auditeerimata esialgne konsolideeritud käive oli 17,07 miljonit eurot. Võrreldes eelmise kvartaliga s.o esimese kvartaliga käive tõusis 33,9% (1kv 2020/2021: 12,74 miljonit eurot), sealhulgas tõusis müük jaekettides 30,7% hulgimüügi sektoris 43,6% ja HoReCa sektoris 14,2%. Eelmise aasta sama perioodiga võrreldes  langes müük 32,9% (2kv 2019/2020: 25,43 miljonit eurot), müügilangus HoReCa sektoris oli 52,7% ja hulgimüügis 60,9%. Jaekettides oli müügitõus 3,2%.Indrek Kasela, PRFoods juhataja kommentaar:„Koroona mõju jätkub kalasektoris ning nagu ka eelmises teates märkisime, et HoReCa sektor, mis moodustab kogu lõhe- ja forellikaubandusest ca 1/3 nii globaalselt kui regionaalselt, ei taastu järgneva 12 kuu jooksul endisele tasemele. Aasta lõpp tõi üle-Euroopaliselt ulatuslikud piirangud jõulude tähistamisel...

Lijnden, January 17, 2021The new name and governance of Stellantis take effectStellantis N.V. (NYSE / MTA / Euronext Paris: STLA) (“Stellantis”) announced today that, following completion of the merger of Peugeot S.A. (“Groupe PSA”) and Fiat Chrysler Automobiles N.V. (“FCA”) on January 16, 2021, today the combined company was renamed Stellantis, the Board of Directors of Stellantis was appointed, and Stellantis’s Articles of Association became effective.

Company announcement 2/2021 (17.01.2021)Based on our preliminary and unaudited reporting, European Energy sees solid growth and raises its expectations for EBITDA in 2020. At the same time, European Energy foresees strong growth for 2021, as the company plans to initiate construction of solar and wind energy capacity for more than one GW and connect around 750 MW to the grid.European Energy is adjusting its expectations for 2020. Despite the Corona-crisis, European Energy has seen solid growth across various business portfolios. Consequently, European Energy now expects an EBITDA of around EUR 60 million in 2020, an increase from the previous guidance interval of between EUR 52-58 million. Profit before tax in 2020 is now expected to reach EUR 37 million which is in line with the expected EUR 35-39 million guidance.Despite the global...

CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021.The final analysis showed an improvement in the secondary endpoint of OS favoring patients randomized to TIBSOVO® compared to those randomized to placebo; however, statistical significance...